On the other hand, based on the significant PARP1 trapping capacity, talazoparib has been clinically employed in breast cancer patients with germline mutations of BRCA1/2 and other types of cancer that contain impaired DNA damage responses [22,74]. Here, PARP1 is linked to cancer.